{"DataElement":{"publicId":"3652825","version":"1","preferredName":"Tamoxifen Discontinued Age Number","preferredDefinition":"the discontinuation of use of the agent tamoxifen._Age","longName":"2010745v4.0:2760628v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2010745","version":"4","preferredName":"Tamoxifen Discontinued","preferredDefinition":"the discontinuation of use of the agent tamoxifen.","longName":"TAM_DXD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2176919","version":"1","preferredName":"Tamoxifen","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04)","longName":"Tamoxifen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AF5-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177545","version":"1","preferredName":"Discontinued","preferredDefinition":"Discontinued; stopped permanently or temporarily.","longName":"Discontinued","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-51CA-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9C67F3E-571C-639C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-06","endDate":null,"createdBy":"PWEST","dateCreated":"2004-05-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2760628","version":"1","preferredName":"Age Number","preferredDefinition":"Age","longName":"2760628v1.0","context":"PS-CC","contextVersion":"1","type":"Non-enumerated","dataType":"java.lang.Integer","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008581","version":"1","preferredName":"Properties or Attributes","preferredDefinition":"NCI Thesarurus C20189","longName":"PropertiesOrAttributes","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C4F36F0A-BEBB-047F-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-15","endDate":null,"createdBy":"DWARZEL","dateCreated":"2003-08-15","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233101","version":"1","preferredName":"Number","preferredDefinition":"Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.","longName":"C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F920A342-1134-2A6A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"501F2599-2A30-4A4E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-20","endDate":null,"createdBy":"UMLLOADER_HINTS","dateCreated":"2008-06-20","modifiedBy":"COOPERM","dateModified":"2011-10-26","changeDescription":"Released VD for use by UAMS CDE. mc 10/26/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"At what age did you STOP taki","type":"Preferred Question Text","description":"At what age did you STOP taking tamoxifen?","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D36B1B10-B147-45C4-E040-BB89AD4326AB","latestVersionIndicator":"Yes","beginDate":"2013-01-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2013-01-16","modifiedBy":"RODGERSC","dateModified":"2015-02-25","changeDescription":"created for UAMS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}